Ottini et al[45], also describe a BRCA2 MBC phenotype with a high proportion of BRE grade 3 tumours (54.8%), loss of PgR expression (67.9%) and HER2 amplification (63.2%). The gene discussed is ERBB2; the disease is neoplasm.